Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies

@article{Zuddas2011SecondGA,
  title={Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies},
  author={Alessandro Zuddas and Robert L Zanni and Tatiana Usala},
  journal={European Neuropsychopharmacology},
  year={2011},
  volume={21},
  pages={600-620}
}

Tables from this paper

Antipsychotics in pediatric and adolescent patients: a review of comparative safety data.

  • L. Ben Amor
  • Medicine, Psychology
    Journal of affective disorders
  • 2012

Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.

Second generation antipsychotics in Asperger's Disorder and high functioning autism: a systematic review of the literature and effectiveness of meta-analysis.

TLDR
There is a lack of robustly conducted trials on the use of SGAs in the management of AD and HFA, so clinicians are cautioned to approach pharmacological treatment prudently balancing benefit with potential cardiometabolic risk.

Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents

  • E. Kirino
  • Psychology, Medicine
    Adolescent health, medicine and therapeutics
  • 2014
TLDR
Aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripIPrazole shows greater efficacy compared to other second-generation antipsychotics.

Absence of Change in Corrected QT Interval in Children and Adolescents Receiving Antipsychotic Treatment: A 12 Month Study.

TLDR
In this sample of treatment-naïve children and adolescents receiving AP treatment, SGA seem to have a safe heart side effect profile in the child and adolescent population.

A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression

TLDR
The findings suggest that when ADHD is comorbid with ODD and aggression MPH and risperidone are both effective on aggressive behavior, but only stimulants are effective on ADHD symptoms.

Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents

  • S. Caccia
  • Psychology, Medicine
    Pediatric Drugs
  • 2013
TLDR
Current evidence indicates that sedation, hyperprolactinemia, and metabolic abnormalities such as excess weight gain, diabetes, and related cardiovascular effects were clinically relevant adverse effects in young patients, with the individual agents differing in their propensity to induce these effects.

Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

TLDR
Despite lacking safety and efficacy data, APP in youth is not uncommon, even in samples predominantly consisting of non-psychotic patients, and no correlation was found with APP definition.
...

References

SHOWING 1-10 OF 132 REFERENCES

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia

TLDR
Preliminary data suggest that SGA use can lead to the development of diabetes in some youth, a disease which itself carries with it significant morbidity and mortality, and the urgent need to develop therapeutic strategies to prevent and/or mitigate weight gain and diabetes early in the course of treatment in this population.

Risperidone in children with autism and serious behavioral problems.

TLDR
Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder and the benefit was maintained at six months.

Risperidone in children with autism and serious behavioral problems.

  • P. Accardo
  • Psychology, Medicine
    The Journal of pediatrics
  • 2003
TLDR
Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder and the benefit was maintained at six months.

Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial.

TLDR
Risperidone, in daily doses of ≥0.01 mg/kg, was significantly more effective than placebo in improving Aberrant Behavioral Checklist (ABC) symptom cluster scores for irritation and hyperactivity.

Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.

TLDR
Metabolic and hormonal side effects of SGAs in children and adolescents should be carefully monitored when prescribing these drugs.

Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.

TLDR
At daily doses of 0.5-2.5 mg and 3-6 mg, risperidone was effective and well tolerated in children and adolescents experiencing acute manic or mixed episodes of bipolar I disorder.

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.

TLDR
Olanzapine may be a promising treatment for improving global functioning of PDDs, but the risk of significant weight gain remains a concern.

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

TLDR
While not demonstrating definitively the superiority of clozapine compared with olanzapine in treatment-refractory childhood-onset schizophrenia, the study suggests that clozamine has a more favorable profile of clinical response, which is balanced against more associated adverse events.
...